Author | David F. McDermott, MD

Articles

Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1–Positive mRCC

March 03, 2017

This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma.